Advanced Filter

Filter by Group

Filter by Market Availability

Did you mean 10 88 0?
Displaying drugs 601 - 625 of 1543 in total
NCX is an NO-releasing derivative of hydrocortisone.
Investigational
CTS-1027 has been used in trials studying the treatment of Hepatitis C and Chronic Hepatitis C Virus Infection.
Experimental
Investigational
CXL-1020 is under investigation in clinical trial NCT01092325 (Safety and Hemodynamic Effects and Pharmacokinetics of CXL-1020 in Patients With Stable Heart Failure).
Investigational
PT886 is a bispecific antibody against Claudin 18.2 and cluster of differentiation 47 (CD47)
Investigational
Prezatide is a tripeptide consisting of glycine, histidine, and lysine which readily forms a complex with copper ions . Prezatide is used in cosmetic products for the skin and hair. It is known to aid wound healing and its potential applications in chronic obstructive pulmonary disease and metastatic colon cancer...
Experimental
Matched Salts cas: … 72957-37-0
AOC-1020 is an antibody oligonucleotide conjugate, comprised of a human transferrin receptor 1 targeting, effector function null, humanized IgG1 antibody, a MCC maleimide linker, and a double-stranded siRNA oligonucleotide targeting DUX4.
Investigational
Leriglitazone is under investigation in clinical trial NCT03917225 (A Clinical Study to Evaluate the Effect of MIN-102 on the Progression of Friedreich's Ataxia in Male and Female Patients).
Investigational
Matched Description: … is under investigation in clinical trial NCT03917225 (A Clinical Study to Evaluate the Effect of MIN-102
TTP889, an orally bioavailable selective inhibitor of the intrinsic coagulation pathway, is being developed as an anticoagulant for the treatment of thromboembolic disorders. TTP889 is the only known selective small molecule inhibitor of Factor IX, a key enzyme of the intrinsic pathway of the blood coagulation system. TTP889 has proven...
Investigational
PHE885 is an investigational, autologous B-cell Maturation Antigen (BCMA)-directed chimeric antigen receptor (CAR)-T cell therapy.
Investigational
Brimapitide is under investigation in clinical trial NCT01570205 (Safety, Tolerability and PK of a Single iv Infusion of 10, 40, and 80 µg/kg XG-102 Administered to Healthy Volunteers).
Investigational
Matched Description: … clinical trial NCT01570205 (Safety, Tolerability and PK of a Single iv Infusion of 10, 40, and 80 µg/kg XG-102
Etirinotecan pegol is under investigation in clinical trial NCT01663012 (Phase II NKTR-102 In Bevacizumab-Resistant High Grade Glioma).
Investigational
Matched Description: … Etirinotecan pegol is under investigation in clinical trial NCT01663012 (Phase II NKTR-102 In Bevacizumab-Resistant …
H3B-8800 is a novel spliceosome inhibitor developed by H3 Biomedicine . It offers the benefit of preferentially killing spliceosome-mutant cancer cells whereas other splicesome inhibitors, such as the pladienolide analogue E7107, show no such preferential targeting . H3B-8800 was granted orphan drug status by the FDA in August 2017 and...
Investigational
Belrestotug is under investigation in clinical trial NCT05565378 (A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/metastatic Non-small-cell Lung Cancer).
Investigational
NV1020, a genetically engineered herpes simplex virus, is a novel anticancer therapeutic.
Investigational
Investigational
Saruparib is under investigation in clinical trial NCT06380751 (Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in Hr-positive, Her2-negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or Palb2m Advanced Breast Cancer).
Investigational
Matched Description: … With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in Hr-positive, Her2-negative (IHC 0, …
REP8839 is a novel methionyl-tRNA synthetase (MetS) inhibitor being developed by Replidyne (GlaxoSmithKline licensed REP8839 to Replidyne in June of 2003).
Investigational
Experimental
AT1022 is a hydromorphone skin patch designed to provide rapid and sustained delivery of a potent opiate for the management of severe pain. AT1022 incorporates PassPort(TM) system, developed to deliver protein and peptide drugs, small-molecule drugs, genes and vaccines across the skin for local and systemic effect.
Investigational
Investigational
Deudomperidone is under investigation in clinical trial NCT05832151 (A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adults With Diabetic Gastroparesis).
Investigational
Matched Description: … under investigation in clinical trial NCT05832151 (A Study to Evaluate the Efficacy and Safety of CIN-102
Carlumab has been used in trials studying the treatment of Cancer and Prostate Cancer.
Investigational
Withdrawn
Asvasiran is an siRNA that targets the respiratory syncytial virus (RSV) N gene and inhibits viral replication. It has the potential to treat or prevent RSV infection.
Investigational
HY10275 is a novel compound specifically designed to modulate two key neurobiological mechanisms that interfere with the sleeping process. HY10275 is highly selective for histamine H1 and serotonin 5HT2a, two chemical receptors that are known to impact the ability to fall asleep and stay asleep. HY10275 was rationally designed to...
Investigational
Investigational
Displaying drugs 601 - 625 of 1543 in total